SNY Key Statistics, Chart & Performance
The current stock price of SNY is 46.59 USD. In the past month the price decreased by -3.24%. In the past year, price decreased by -8.2%.
SNY Technical Analysis
SNY Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to SNY. SNY has an excellent profitability rating, but there are concerns on its financial health.
SNY Financial Highlights
Over the last trailing twelve months SNY reported a non-GAAP Earnings per Share(EPS) of 4.43. The EPS decreased by -5.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.63% | ||
| ROA | 10.63% | ||
| ROE | 18.84% | ||
| Debt/Equity | 0.18 |
SNY Forecast & Estimates
29 analysts have analysed SNY and the average price target is 62.25 USD. This implies a price increase of 33.62% is expected in the next year compared to the current price of 46.59.
For the next year, analysts expect an EPS growth of 2.37% and a revenue growth -0.09% for SNY
SNY Ownership
SNY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.31B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About SNY
Company Profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Company Info
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008 FR
CEO: Paul Hudson
Employees: 82878
Phone: 33153774000
SANOFI-ADR / SNY FAQ
What does SNY do?
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Can you provide the latest stock price for SANOFI-ADR?
The current stock price of SNY is 46.59 USD. The price decreased by -1.85% in the last trading session.
Does SANOFI-ADR pay dividends?
SANOFI-ADR (SNY) has a dividend yield of 4.73%. The yearly dividend amount is currently 2.21.
How is the ChartMill rating for SANOFI-ADR?
SNY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about SANOFI-ADR (SNY) stock?
29 analysts have analysed SNY and the average price target is 62.25 USD. This implies a price increase of 33.62% is expected in the next year compared to the current price of 46.59.
Can you provide the sector and industry classification for SANOFI-ADR?
SANOFI-ADR (SNY) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of SNY stock?
SANOFI-ADR (SNY) has a market capitalization of 113.17B USD. This makes SNY a Large Cap stock.